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Breast cancerRecent studies reported that protein arginine methyltransferase 6 (PRMT6) enhances estrogen-induced activity
of estrogen receptorα (ERα) and dysfunction of PRMT6 is associatedwith overall better survival for ERα-positive
breast cancer patients. However, it is unclear how PRMT6 promotes ERα activity. Here we report that PRMT6
speciﬁcally interacts with ERα at its ligand-binding domain. PRMT6 also methylates ERα both in vitro and
in vivo. In addition to enhancing estrogen-induced ERα activity, PRMT6 over-expression up-regulates
estrogen-independent activity of ERα and PRMT6 gene silencing in MCF7 cells inhibits ligand-independent
ERα activation. More interestingly, the effect of PRMT6 on the ligand-independent ERα activity does not require
itsmethyltransferase activity. Instead, PRMT6 competeswithHsp90 for ERα binding: PRMT6andHsp90bindings
to ERα are mutually exclusive and PRMT6 over-expression reduces ERα interaction with Hsp90. In conclusion,
PRMT6 requires its methyltransferase activity to enhance ERα's ligand-induced activity, but its effect on
ligand-independent activity is likely mediated through competing with Hsp90 for binding to the C-terminal
domain of ERα. PRMT6-ERα interaction would prevent ERα-Hsp90 association. Since Hsp90 and associated
chaperones serve to maintain ERα conformation for ligand-binding yet functionally inactive, inhibition of
ERα-Hsp90 interaction would relieve ERα from the constraint of chaperone complex.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Estrogen receptor (ER) is a member of the nuclear receptor super-
family and it is essential for the development of reproductive tract,
mammary gland, skeletal and central nervous system [1,2]. There are
two isoforms of ER, ERα and ERβ. Despite the high level of homology
in sequence and structure between these two isoforms, selective
knock out of ERα or ERβ in mice revealed that they have distinct
biological functions in different tissues [1,3,4]. In the mammary
gland, ERα promotes breast cell proliferation whereas ERβ is anti-
proliferative [5,6]. Over-expression of ERα in the mammary gland
of transgenic mice model results in hyperplasia [7].
ERα has a conserved domain structure common to nuclear
receptors, consisting of the N-terminal variable region (VR), a central
DNA-binding domain (DBD), a hinge region linking DBD and the
C-terminal ligand binding domain (LBD). There is also an additional
region F at the C-terminal end of ERα which may be involved in the
interaction with antagonist [8]. Activity of ERα is regulated by twor Genetics and Cell Biology,
ical University, 60 Nanyang
65 6791 3856.activation functions (AF), AF-1 in the VR is constitutively active and
AF-2 in LBD is activated by ligand binding. These two activation
functions exhibit both independent and synergistic activities [9].
The mechanism of ligand-induced ERα activation involving AF-2
has been studied extensively. Unliganded ERα associates with the
chaperone protein complex consisting of the heat shock protein
90 (Hsp90), p23 and several other molecules. These chaperone
proteins are essential for the proper folding of ERα, keeping it inac-
tive while maintaining it in a conformation favorable for ligand
binding [10–12]. Upon estrogen binding to the LBD of ERα, activated
ERα undergoes conformational changes and is released from the
Hsp90 chaperone complex. It can then bind to speciﬁc DNA sequences
and recruit coregulators on the target promoter to modulate gene
transcription [13]. In addition, the liganded ERα can also regulate
gene transcription by tethering to other DNA binding proteins such as
activator protein 1 (AP-1) and stimulating protein 1 (Sp1) [14,15].
Activation of ERα by estrogen or cell signaling molecules sustains
breast cancer progression in at least 50% of breast cancers. Current
treatment for the ERα positive breast cancermainly targets its hormone
induced signaling pathway; either through the use of selective estrogen
receptor modulators (SERMs) or the direct inhibition of estrogen
production by targeting aromatase [16,17]. SERMs such as tamoxifen
can act as ERα antagonist in the mammary gland, compete with
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tion [18]. However, it has been found that the efﬁcacy for endocrine
treatment is often limited by intrinsic or acquired anti-estrogen
resistance which can be due to the increase in ligand-independent
activity of ERα involving AF-1 [19]. This activation of ERα in the
absence of hormone can occur either by post-translational modiﬁcation
(PTM) or by direct cofactor binding [20–22]. For instance, epidermal
growth factor (EGF) activates ERα through the phosphorylation of
serine 118 bymitogen-activated protein kinase (MAPK) and phosphor-
ylation of serine 167 by 90 kDa ribosomal S6 kinase (RSK) [23–25].
The increase in MAPK activity has been observed for both estrogen-
independent breast cancer cell lines models [26] and human breast
cancers [27]. Higher MAPK activity also correlates with poorer
response to endocrine treatments and shorter survival for breast
cancer patients [28].
The activation of ERα by direct cofactor binding also plays an impor-
tant role in breast cancer development. Cyclin D1 binding to ERα
LBD has been found to promote the recruitment of steroid receptor
coactivators to ERα and ERα binding toDNA, hence activating transcrip-
tion in the absence of estrogen [21,29]. A meta-analysis involving 2580
breast cancer patients showed that over-expression of cyclin D1 pre-
dicts worse survival in the ERα-positive breast cancer subgroup [30].
Human X box-binding protein 1 (XBP-1) can also interact with ERα
DBD to enhance the ligand-independent activity of ERα [22]. It is highly
expressed in breast tumors [31] and ectopic over-expression of XBP-1 in
breast cancer cell line model showed increased estrogen-independent
growth and decreased sensitivity to anti-estrogen [32]. Further
understanding on this complex ERα regulatory network is critical
in the development of new therapy for anti-estrogen resistance.
Recent studies showed that protein arginine methyltransferases
(PRMTs) act on multiple aspects of ERα signaling through different
mechanisms. PRMT1, 2, 4 and 6 enhance the ligand induced activity of
ERα, most probably by methylating and potentiating the activity of
ERα coactivators [33–35]. PRMT1 can also enhance the cytoplasmic
ERα signaling by directly methylating ERα at arginine 260 [36]. In addi-
tion, PRMT6 regulates breast cancer cell proliferation directly; depletion
of PRMT6 in breast cancer cells completely inhibits their ability to form
breast tumors after injection into mouse mammary fat pad [37]. This
effect of PRMT6 on cells growth may be partly attributed to its negative
regulatory action on the expression of tumor suppressors p53 and p21
[37–40]. However, microarray analysis of breast cancer cell lines and
breast tumors gene expression proﬁle showed that PRMT6 dysfunction
associates speciﬁcally with gene expression signature for better overall
relapse-free and distant metastasis-free survival in the ERα-positive
breast cancer subgroup [41], suggesting that the oncogenic activity of
PRMT6 is also mediated through ERα signaling. In this study, we dem-
onstrate that PRMT6 interacts with and methylates several steroid hor-
mone receptors, ERα, PRB and AR. More importantly, PRMT6 enhances
the ligand-independent activity of ERα and this effect is methyltrans-
ferase activity-independent. We also provide evidence suggesting that
PRMT6 enhances the ligand-independent activity of ERα by reducing
the pool of ERα that is associated with the Hsp90 chaperone complex
which keeps ERα inactive in the absence of ligand. Our results suggest
that PRMT6 may contribute to worse prognosis by promoting estrogen-
independent growth of ERα-positive breast cancer.
2. Materials and methods
2.1. Plasmid constructs
PRMT1 to PRMT8 were cloned into pcDNA3.1+/hygro plasmid
using primers containing 1X Flag tag in the forward sequence.
PRMT2, 4, 5, 6 and 8 in GFP vector were gifts from Dr. Mark Bedford
(The University of Texas M.D. Anderson Cancer Center); PRMT1,
3 and 7 MGC clones were given by Dr. Tobias Cornvik (Nanyang
Technological University, Singapore). pSG5-GR plasmid was a giftfrom Dr. Ravi Kambadur (Nanyang Technological University, Singapore).
pCMV5-Flag-ERα and pCMV5-Flag-AR were gifts from Dr. Edwin
Cheung (Genome Institute of Singapore). pCR3.1-SRC-1 plasmid
was a gift from Dr. Ming-Jer Tsai (Baylor College of Medicine,
Houston, Texas). Various ERα truncation constructs were generated
by amplifying different ERα segments using speciﬁc primers targeting
each region. ERα (R260K) mutant was generated using site-directed
mutagenesis XL II kit with the primer set 5′-gtgggatacgaaaagaccga
aagggagggagaatgttgaaa-3′ and 5′-tttcaacattctccctccctttcggtcttttcgtatc
ccac-3′ (Stratagene, La Jolla, CA, USA).
2.2. Cell culture and transfection
All cancer cell lines were routinely maintained in phenol red-
containing Dulbecco's modiﬁed Eagle's medium (DMEM) (PAA
Laboratories Ltd., Somerset, UK) supplemented with 7.5% fetal bovine
serum (FBS) (Sigma-Aldrich, St. Louis,MO, USA) and 2mML-glutamine
(PAA Laboratories Ltd). Cells were plated in phenol red-free DMEM
supplemented with 5% dextran-coated charcoal-treated FBS (DCC-FBS)
for 48 h before hormone treatment to remove the residual effect of
hormones from serum.
Plasmid transfection was carried out using polyethyleneimine (PEI)
(Polysciences, Warrington, PA, USA) according to the cellntec advanced
cell systems transfection protocol for PEI (1 μg plasmid: 1.5 μl PEI
for each 35 mm dish). Transfection of siRNA was carried out using
Lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA) according
to manufacturer's instruction. siRNAs were purchased from Ambion
(Austin, TX, USA, negative control:4390844. PRMT6 siRNA1: s30337,
PRMT6 siRNA2: s30338).
2.3. Co-immunoprecipitation (Co-IP) cellular fractionation and Western
blotting
Total cell lysates were collected as described in [42] and incubated
with 1 μg of antibody plus protein A/G agarose beads (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) or incubated with anti-Flag afﬁnity
gel (Flag beads) (Sigma-Aldrich). Both beads and supernatant were
loaded for Western blotting analysis as described earlier [42].
Nitrocellular membranes were cut horizontally into strips to probe
for proteins of interest with different molecular weights and aligned
back for developing in some experiments.
For cellular fractionation, COS7 cellswere pelleted and re-suspended
in buffer C1 (10 mM Hepes pH7.9, 1.5 mM MgCl2, 10 mM KCl, 0.1%
NP40, 10 mM DTT, 5 μg/ml pepstatin A, 5 μg/ml leupeptin, 2 μg/ml
aprotinin), incubated on ice for 10min and passed through 21G syringe
for 10 times. The supernatant after centrifugation at 1000 g was kept
as the cytoplasmic fraction. Pellet was washed once in buffer C1, re-
suspended in buffer N1 (10 mM Hepes pH7.9, 1.5 mM MgCl2, 10 mM
KCl, 0.5% NP40, 10 mM DTT, 5 μg/ml pepstatin A, 5 μg/ml leupeptin,
2 μg/ml aprotinin) and nuclei were broken down using a 29G syringe,
followed by centrifugation (12,000 g, 10 min) to obtain the nuclear
soluble fraction in the supernatant. Final pellet were re-suspended in
buffer N2 (10 mM Hepes pH7.9, 1.5 mM MgCl2, 0.4 M KCl, 0.3 M
sucrose, 0.5%NP40, 10mMDTT, 5 μg/ml pepstatin A, 5 μg/ml leupeptin,
2 μg/ml aprotinin) and passed through 29G syringe for 10 times, spun
down at 20,000 g for 15 min to obtain the chromatin-bound fraction.
Antibodies used in this study are anti-Flag (F1804, Sigma-Aldrich),
anti-GAPDH (AM4300, Ambion), anti-Histone H3 (#9715, Cell signaling).
Anti-ERα (sc-002, sc-543), anti-GR (sc-8992), anti-Hsp90 (sc-13119),
anti-PRMT6 (sc-271744) and anti-PRB (sc-7208) were purchased from
Santa Cruz Biotechnology.
2.4. Immunostaining and proximity ligation assay (PLA)
Cells on cover slip were ﬁxed with 3.7% formaldehyde and
permeabilized with 0.2% triton-X 100 (Sigma-Aldrich). After blocking
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(anti-ERα and anti-Flag) followed by secondary antibodies (Dylight
594 Goat anti-mouse IgG (H + L) (115-515-166): from Jackson
ImmunoResearch, Suffolk, UK and Alexa Fluor 488 nm anti-rabbit
IgG (H + L) (A11034) with 4′,6-diamidino-2-phenylindole (DAPI)
(0.1 μg/ml) (Life Technologies)).
For PLA, cellswere plated on aNunc latek chamber slide (NalgeNunc
International, Rochester, NY, USA). After overnight incubation at 4 °C
with primary antibodies, samples were processed using Duolink II PLA
kit (Olink Bioscience, Uppsala, Sweden) according to manufacturer's
manual. Brieﬂy, samples were incubated with anti-mouse and anti-
rabbit PLA probes for 1 h at 37 °C, followed by ligation reaction mix
incubation for additional 30 min at 37 °C. Signal was ampliﬁed using
ampliﬁcation-polymerase for 100 min at 37 °C. The slide was then
washed and mounted for viewing. Detection reagent orange (ex/em
554/579) was used in this experiment.
2.5. Luciferase reporter assay
For luciferase reporter assay, HeLa cells in 60 mm dishes were
transfected with 1.5 μg of PRE-luciferase or ERE-luciferase, 5 ng of re-
ceptor coding plasmids, with 25–50 ng of PRMT6 plasmids (the amount
of plasmids was scaled down to 1/3 if transfection was done in 6-well
plate, i.e. 1.6 ng of receptor plasmid and 16 ng of PRMT6 plasmid).
Cellswere treatedwith 10nMof the respective hormone (17β-estradiol
(E2) for ERα, progestin R5020 for PRB, dihydroxytestosterone (DHT) for
AR and dexamethasone (Dex) for GR) for 24 h after being transfected
for 24 h. Lysate was collected for analysis using Promega Luciferase
assay kit (Promega, Madison, WI, USA). For MCF7 cells, they were
ﬁrst transfected with PRMT6 siRNA for 24 h, followed by another
24 hour transfection with ERE-Luciferase before treated with hormone
for 24 h. Luciferase signals were detected using Tecan Saﬁre II Plate
Reader and normalized with protein concentration quantiﬁed by
Pierce BCA Protein Assay Kit (Pierce Biotechnology Inc, Rockford,
IL, USA). Student's t test was conducted and a p value less than 0.05
is considered signiﬁcant.
2.6. Reverse transcription and real-time PCR
Total RNA was extracted using TRIzol reagent (Life Technologies),
chloroform:isoamyl-ethanol (24:1) and phenol:chloroform:isoamyl-
ethanol (50:24:1, Sigma-Aldrich), precipitated using isopropanol and
washedwith 75%ethanol inDEPC-treatedwater (Sigma-Aldrich) before
re-suspending in DEPC-treated water. cDNA was synthesized from 1 to
5 μg of total RNA using random primer (Promega) and SuperScript II™
reverse transcriptase (Life Technologies). Real-time PCRwas performed
using KAPA SYBR Green PCR reagents on an ABI Prism 7000 Sequence
Detection System (Applied Biosystems, Carlsbad, CA, USA) according
to the manufacturer's protocol. PCR for each gene was performed in
triplicates. The relative amount of PCR products generated from each
primer setwas determined on the basis of the threshold cycle (Ct) num-
ber. Housekeeping gene 36B4 was used as control to normalize the
amount of cDNA used. Relative expression = 2 [[Ct(control)gene X− Ct
(treatment)gene X] − [Ct(control)36B4 − Ct(treatment)36B4]].
Primer sequences are available upon request.
2.7. In vitro and in vivo methyltransferase assay
In vitro methyltransferase assay for PRMT6 was performed in
methylation buffer containing 100 mM of Tris pH 8.0, 25 mM MgCl2
and 0.004 M DTT. 0.55 μCi of H3-S-adenosyl L-methionine (H3-SAM,
PerkinElmer, Waltham, MA, USA) was used for each reaction. Flag
tagged receptors and PRMT6 plasmids were transfected into COS7
cells and pulled down with Flag beads. Beads were incubated in
the methylation buffer for 1 h at 37 °C with shaking. Reaction was
quenched using protein loading dye. Samples were separated bySDS-PAGE and stained with coomassie blue. Signal was enhance using
ELIGHTENING solution (PerkinElmer). Gels were dried in GelAir dryer
(Bio-Rad, Richmond, CA, USA) and dried gels were kept with hyperﬁlm
MP (GE Healthcare Biosciences, Pittsburgh, PA, USA) for 1–3 weeks
at−80 °C to detect the radioactivity.
In vivomethyltransferase assay was carried out by over-expressing
Flag-ERα in the presence and absence of Flag-PRMT6. 24 h after trans-
fection, cells were treated with 20 μM Adenosine, periodate oxidized
(AdOx, Sigma-Aldrich) for 24 h to inhibit protein methylation. Cells
were then pretreated with 100 μg/ml of cycloheximide and 40 μg/ml
of chloramphenicol (Sigma-Aldrich) for 30 min to inhibit protein
synthesis followed by labeling with H3-methione (PerkinElmer) for
additional 3 h. Lysates were collected for immunoprecipitation with
Flag beads and processed as mentioned in the paragraph above.
3. Results
3.1. PRMT6 interacts with ERα, PR and AR independent of ligand binding
To search for the PRMT that can interact with ERα directly and
hence may target ERα for methylation, Flag tagged PRMT1 to
PRMT8 co-expressed with ERα in COS7 cells were immunoprecipitated
with anti-Flag antibody. Although anti-Flag antibody was able to
pull down all eight PRMTs speciﬁcally (note that PRMT2 band
partially overlaps with Ig Heavy chain at 50 kDa), ERα was only
co-immunoprecipitated with PRMT2 and PRMT6 in the absence of
hormone treatment (Fig. 1 A). While this ﬁnding is consistent with a
previous report that PRMT2 coactivates and interacts with ERα [34], it
is the ﬁrst demonstration that PRMT6 interacts speciﬁcally with ERα.
Further validation for this interaction was carried out with reverse IP
using anti-ERα antibody. As shown in Fig. 1 B, PRMT6 was pulled
down by anti-ERα antibody speciﬁcally.
We then examined if PRMT6 can interact with multiple steroid
hormone receptors and if the interaction is regulated by hormone
treatment. Co-IP was performed using COS7 cells over-expressing
ERα, PRB, AR or GR together with PRMT6. Transfection with pcDNA3.1
vector in place of PRMT6 was used as a control. As shown in Fig. 1 C to
1F, PRMT6 co-immunoprecipitated ERα, PRB and AR. However, no GR
protein could be pulled down by PRMT6. In addition, the amount of
ERα/PRB/AR protein pulled down by PRMT6 was down-regulated in
the presence of hormone treatment, although there was no signiﬁcant
decrease in the input protein level after 6 h of hormone treatment,
suggesting that PRMT6 preferentially binds to unliganded receptors.
3.2. PRMT6 methylates ERα, PRB and AR
Whilewe showed that PRMT6 interactswith ERα, PRB and AR, it has
not been demonstrated if PRMT6 can methylate these receptors.
We tested this by in vitro methyltransferase assay using Flag-tagged
PRMT6 and Flag-tagged ERα/PRB/AR co-expressed in COS7 and pulled
down by anti-Flag afﬁnity gel (Flag beads). Proteins attached to the
Flag beads were at close proximity which facilitated the methylation
reaction. Flag-PRMT6, Flag-ERα and Flag-AR were pulled down well as
shown by the bands on coomassie blue stained gel but less Flag-PRB
was pulled down and it appeared close to a background band (Fig. 2 A).
Autoradiogram showed that PRMT6 was capable of self-methylation as
reported [43], indicating that the methylation reaction occurred success-
fully. Prominent autoradiograph bands corresponding to the size of
PRB, ERα and ARwere seen. ERαmethylation bandwas the strongest
and PRBmethylation bandwasmuchweaker and appeared just below a
background band, maybe due to the lower amount of proteins pulled
down. Flag-PRMT2 was also included in the assay, showing that
PRMT2 can also self-methylate, but it was unable to methylate the
other co-immunoprecipitated proteins shown on the coomassie blue
stained gel (less bands on the autoradiogram as compared to PRMT6),
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highly speciﬁc (Fig. 2 A).
As in vitromethylation labels target proteins after they are isolated
from the cells, we also determined if PRMT6 can methylate ERα in live
cells. In vivo labeling with H3-methionine in the presence of protein
synthesis inhibitor was carried out for ERα with and without PRMT6
over-expression. The amount of ERα and PRMT6 proteins detected
was lower than in vitro methylation assay due to the treatments
that inhibited protein synthesis. Nonetheless, ERαwas clearly meth-
ylated in the presence of PRMT6 with or without hormone treatment
(Fig. 2 B). In contrast, ERα was not methylated in the absence
of PRMT6 over-expression. As a positive control, PRMT6 was also
methylated, likely by itself (Fig. 2 B).
3.3. PRMT6 methylates ERα at arginine 260
Amino acid sequence analysis for ERα revealed that arginine 260
is present in the ‘RGG’ recognition motif and is possible target of
PRMT6. In vitro methylation of ERα(R260K) mutant showed signiﬁ-
cant decrease in the methylation signal as compared to the wild-
type ERα. As shown in Fig. 2 C, although PRMT6 could still methylate
ERα(R260K), the methylation signal was weakened by more than
50% after normalization with protein level, suggesting that ERα
is methylated by PRMT6 at more than one arginine sites and R260
is one of the target site. In addition, the speciﬁcity of PRMT6methylation on ERαwas further demonstrated using the enzymatically
inactive mutant mPRMT6 (V86K/D88A). Although both ERα and
mPRMT6 protein levels were high in the coomassie stained gel,
no ERα methylation band could be seen in the autoradiogram,
conﬁrming that the presence of active PRMT6 was needed for the
labeling on ERα to occur (Fig. 2 C).When ERα(R260K)mutant's activity
was analyzed by ERE-Luciferase reporter assay, no signiﬁcant change
was detected as compared to wild-type ERα (See Supplementary
Fig. 1), suggesting that PRMT6methylation of R260may not be involved
in regulating the genomic signaling of ERα.3.4. PRMT6 binds to ERα in the nucleus in vivo
It has been reported [35] that PRMT6 interacts with SRC-1 to act
as a secondary coactivator for ERα. Consistent with the ﬁnding,
we also found that PRMT6 interacts with SRC-1 in the absence
of ERα (Fig. 3 A). However, SRC-1 and ERα interaction is largely
E2-dependent (Fig. 3 B). We also observed that PRMT6 preferentially
bound to ERαwhen both ERα and SRC-1 were present (Fig. 3 C), sug-
gesting that PRMT6 has higher afﬁnity for unliganded ERα than for
SRC-1. It is possible that PRMT6 exhibits two modes of interaction
with ERα: it binds to unliganded ERα directly but binds to liganded
ERα through SRC-1. Hence PRMT6 may be involved in multiple
aspects of ERα signaling.
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breast cancer cells, MCF7 cells stably expressing either pcDNA3.1 vector
or Flag-PRMT6 vector were established for immunostaining and PLA.
Consistent with a previous study [43], immunostaining showed that
PRMT6 protein mainly localizes in the nucleus. Majority of ERα protein
was also present in the nucleus (Fig. 4 A, top). After E2 treatment,
PRMT6 remained in the nucleus, whereas ERα protein showed de-
creased cytoplasmic staining (Fig. 7 A, bottom). The co-localization
of PRMT6 and ERα was further demonstrated by PLA. Red dots repre-
sent positive signal ampliﬁcation that occurs if the two proteins are in
close proximity (b40 nm). In the negative control with pcDNA3.1
transfected, none or very few red dots were seen after PLA staining,
showing that the assay is highly speciﬁc. In the presence of Flag-
PRMT6, numerous red dots were seen in the nucleus of both ethanol-
and E2-treated samples, indicating that Flag-PRMT6 interacted with
endogenous ERα speciﬁcally in the nucleus (Fig. 4 B). Furthermore,
E2-treated cells contain fewer but larger ERα-PRMT6 interaction spots
than the ethanol treated cells. The larger PLA signal dots in E2-treated
cells compared to the ethanol treated controls (also see Supplementary
Fig. 2) suggest more concentrated ERα-PRMT6 interactions and hence
E2-induced ERα re-organization of its nuclear loci [44]. It has been
well documented that transcription regulation involves dynamic
chromatin conﬁgurationwith RNA polymerase II clustered into discrete
transcription loci known as transcription factories [45,46]. Ligand-
activated ERα has been reported to instigate reorganization of these
transcription factories by recruiting its target genes [44]. It is plausible
that these ERα–PRMT6 interaction spots are concentrated in the
transcription factories organized by ligand-activated ERα.
Although co-immunoprecipitation experiment showed decrease
of ERα and PRMT6 interaction following E2 treatment, it is not
clear from the PLA images if there is a decreased interaction between
ERα and PRMT6 upon E2 treatment. Cell fractionation experiment
(Fig. 4 D) showed that E2 treatment increased the proportion of
ERα binding to chromatin, suggesting that the decrease in ERα and
PRMT6 interaction by co-immunoprecipitation experiment following
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2072 Y. Sun et al. / Biochimica et Biophysica Acta 1843 (2014) 2067–2078E2 treatment may be caused by the change in ERα localization. The
chromatin associated ERα would not be extracted efﬁciently by the
routine IP buffer, leading to decreases in PRMT6-ERα interaction. On
the other hand, there is no signiﬁcant increase of chromatin-bound
PRMT6 in response to E2 treatment in spite of its co-localization with
ERα (Fig. 4 D). It is possible that PRMT6 is recruited to the transcription
loci by associating with other co-regulatory proteins recruited byE2-activated ERα. But it is not stably associated with the chromatin
and can be eluted with high salt buffer. This notion is consistent
with an earlier report that PRMT6 acts as a secondary coactivator
for the ligand-activated ERα [35].
As was expected, both ERα and PRMT6 are found mainly in the
nuclear and chromatin fractions. But these proteins are also present
in large amount in the cytoplasmic fraction (Fig. 4 D), which can be
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proteins was continuously synthesized in the cytoplasm following
transient transfection.
3.5. PRMT6up-regulates ligand-independent activity of ERα independent of
its enzymatic activity
In agreement with a previous report [35], PRMT6 coactivates the
hormone induced transcriptional activity of PRB, GR, AR and ERα
in the luciferase reporter assay in HeLa cells (Fig. 5 A to C, Fig. 6 A).
In addition, our study showed that PRMT6 doubled the ligand-
independent activity of ERα (Fig. 6 A). Surprisingly, this effect of
PRMT6 on the ligand-independent activity of ERα is independent
of its methyltransferase activity as the inactive mutant mPRMT6 en-
hanced the ligand-independent activity of ERα similarly. In contrast,
the ligand-induced ERα activity was only up-regulated by wild-type
PRMT6 but not mPRMT6, consistent with the earlier report by
Harrison et al. [35]. This suggests that PRMT6 regulations of the
ligand-independent and ligand-dependent ERα activity are mediated
through different mechanisms (Fig. 6 A). It should be noted that the
mutant PRMT6 protein expression level is consistently lower than that
of the wild-type PRMT6 and the cause is not clear (Fig. 6 D). In spite
of this low expression level, mPRMT6 signiﬁcantly enhanced the
ligand-independent activity of ERα. It is also important to note that
the ligand-independent ERE luciferase activity can be reduced by 70%
using speciﬁc ERα antagonist ICI 182780 (Fig. 6 B), conﬁrming that
the observed transcriptional activity is ERα speciﬁc. On the other
hand, it is expected that there is some remaining ERα activity (30% in
this case) depending on the dose and duration of ICI 182780 treatment.
Interestingly, wild-type PRMT6 or mPRMT6 over-expression also en-
hanced the remaining ligand-independent activity of ERα followingICI 182780 treatment (Fig. 6 B). Similarly, while tamoxifen decreased
the ligand-independent activity of ERα by 50%, PRMT6 over-expression
doubled the ERα activity in the presence of tamoxifen, to a level that
is higher than the control ERE luciferase activity without tamoxifen
treatment (Fig. 6 C). Protein expression of ERα in HeLa cell was analyzed
byWestern blotting to show that the change in activity detected was not
contributed by increase in the ERα protein level (Fig. 6 D).
The positive effect of PRMT6 on the ligand-independent activity of
ERα is also demonstrated in breast cancer cells MCF7. Knockdown of
endogenous PRMT6 in MCF7 cells decreased both ligand-independent
and ligand-dependent ERα activities without a signiﬁcant effect on
ERα's expression level (Fig. 7 A and D). ERα direct target genes
pS2 and GREB1 were also down-regulated upon PRMT6 knockdown
(Fig. 7 B). When the effect of PRMT6 on MCF7 cell proliferation was
analyzed by cell counting, depletion of PRMT6 by transient transfection
of siRNA caused 40% decrease in cell number after 4 days, bothwith and
without hormone treatment (Fig. 7 C).
3.6. Competitive binding between PRMT6 and Hsp90
We next investigated the possible mechanisms by which PRMT6
enhances ligand-independent activity of ERα. It is well known that
Hsp90 is an important component of the steroid receptor protein
complex in the absence of ligand and this complex formation is critical
for receptor folding, maturation and dimerization while keeping the
receptors in an inactive state [10,11,47]. Since PRMT6 binds to the
unliganded ERα better, we examined if PRMT6 was also part of this
pre-activation chaperone complex. Although ERα binds to both Hsp90
and PRMT6 (Fig. 8 A), Hsp90 and PRMT6 seem to exist in distinct com-
plexes with ERα. While both wild-type and mutant PRMT6 could pull
down ERα well, no Hsp90 was pulled down concurrently (Fig. 8 B).
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ERα but not PRMT6 (Fig. 8 C). These data suggest that PRMT6 and
Hsp90 bindings to ERα are mutually exclusive. The efﬁciency of Hsp90
pull down by ERα was then compared in the absence and presence of
exogenous PRMT6. As shown in Fig. 8 D, the amount of Hsp90 pulled
down by ERαwas drastically reduced in the presence of PRMT6, despite
similar expression levels of Hsp90 and ERα. This demonstrates that
PRMT6 can compete with Hsp90 directly for binding to ERα, increased
PRMT6 binding to ERα results in a decrease in ERα/Hsp90 interaction.
3.7. PRMT6 binds to ERα at the C-terminal LBD-F region
It has been reported that Hsp90 binds to the DBD-LBD region of ERα
[48].We asked the question if PRMT6 binds to ERα in this region aswell.
Co-immunoprecipitation showed that deletion of the variable region of
ERα (amino acid 1–185) (ΔVR) did not reduce PRMT6-ERα interaction,
suggesting that VR is not required for the interaction (Fig. 8 E). Vectors
containing VR only (amino acid 1–185), VR to hinge region (amino acid
1–355) and LBD to region F (amino acid 356–595) were then tested. As
expected, VR alone could not interact with PRMT6. ERα ΔLBD also did
not bind to PRMT6. However, LBD to region F alone was sufﬁcient to
interact with PRMT6. Although the protein expression level for LBD to
region F was lower than the other domains, it could be pulled down
by PRMT6 very well, at a level that was much higher than the input
control (Fig. 8 F). The ﬁndings that both Hsp90 and PRMT6 interact
with ERα LBD may explain their mutually exclusive and competitivebinding with ERα. We speculate that PRMT6 increases the ligand-
independent activity of ERα by freeing ERα from the inactivating effect
of Hsp90 chaperone complex.
4. Discussion
PRMT6 expression is generally low in normal tissue but over-
expressed in a signiﬁcant number of tumors including breast tumors
[37,49]. Serum level of asymmetrical dimethylarginine is also elevated
in breast cancer patients, which may be partly caused by the higher
PRMT6 activity in cancer and contribute to tumor progression [49].
Recent studies on the involvement of PRMT6 in breast cancer also
reported that PRMT6 dysfunction is associated with better overall sur-
vival in the ERα-positive breast cancer [41] and PRMT6 silencing abol-
ishes the tumor forming ability of breast cancer cells in mouse model
[37]. Here we report that PRMT6 binds to ERα speciﬁcally using both
co-immunoprecipitation and proximity ligation assay in the presence
or absence of estrogen. PRMT6 also enhances both ligand-dependent
and ligand-independent activity of ERα. We provide evidence to sug-
gest that these two effects are mediated through distinct mechanisms.
In agreement with a previous study [35], the effect of PRMT6 on
ligand-induced ERα activity is methyltransferase activity-dependent.
On the other hand, the stimulatory effect of PRMT6 on ligand-
independent activity of ERα does not require the enzymatic activity.
This effect of PRMT6 on the ligand-independent activity of ERα is very
prominent in our assays but it was not reported [35]. One possible
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amount of plasmid vector and ERα/PRMT6 plasmid ratios from the
earlier study. Harrison et al. used 15 ng ERα/50 ng PRMT6 vector in
24-well plates in the transfection [35]. We used 1.6 ng ERα/16 ng
PRMT6 vector in 6-well plates. They and earlier study [33] also noted
that a greater coactivating effect was observed with lower amount
of nuclear receptor transfected. Our observation that ERα activity
decreased after knockdown of endogenous PRMT6 inMCF7 cells further
support that PRMT6 can enhance the ligand-independent activity of
ERα specially.
Our data suggest that the ligand-independent PRMT6-ERα interac-
tion plays a key part in enhancing the ligand-independent ERα activity.
Unliganded ERα is associated with chaperone protein complex
consisting of Hsp90, cyclophilin 40, p23, etc. Interaction with the
chaperone proteins not only facilitates proper folding of the receptor
for ligand binding, but also keeps ERα in an inactive state in the absence
of ligand [10–12,47]. We found that PRMT6-ERα and Hsp90-ERα
bindings were mutually exclusive. While immunoprecipitation of
ERα pulled down both PRMT6 and Hsp90, immunoprecipitated
PRMT6 was only associated with ERα but not Hsp90. Similarly,
immunoprecipitated Hsp90 was associated with ERα but not PRMT6.
Moreover, over-expression of PRMT6 leads to a decrease in the interac-
tion between ERα and Hsp90 directly. This implies that the ligand-
independent PRMT6-ERα interaction may prevent ERα association
with Hsp90 and other associated chaperone proteins that normally
keep ERα inactive. Meanwhile, PRMT6-bound ERα can still be the func-
tionally mature form from the Hsp90 complex. Therefore, competitive
binding of ERα between PRMT6 and Hsp90 does not reduce the pool
of structurally mature ERα. Consequently, there is a greater propensity
for ERα to be activated. It is also interesting to note that the enzymati-
cally inactive PRMT6 mutant interacted with ERα equally well as the
wild-type PRMT6, which is also consistent with its equally potent effecton enhancing the ligand-independent activation of ERα. This further
supports the notion that the ligand-independent activation of ERα by
PRMT6 is mediated through their ligand-independent interaction but
not caused by the methyltransferase activity of PRMT6. In addition,
the fact that PRMT6 mutant did not have any effects on the ligand-
induced ERα activity conﬁrmed that PRMT6's effect on the ligand-
independent activity of ERα is different from its action on the liganded
ERα and it is highly speciﬁc. This ruled out the possibility that the
observed ligand-independent activity was a result of residual hormone
in the medium.
Analysis of ERα domain truncations indicated that the site of its
ligand-independent interaction with PRMT6 lies in the LBD-F region
(amino acid 356–595). This interaction is attenuated in the presence
of estrogen, suggesting that ligand binding alters the conformation of
the interaction interface, resulting in the impaired interaction with
PRMT6. Interestingly, ERα also interacts with Hsp90 via its C-terminus
region including the LBD [48]. Since both PRMT6 and Hsp90 bind to
ERα at its C-terminus [48], it is likely that PRMT6 can compete with
Hsp90 for binding to ERα, resulting in the dissociation of ERα from
chaperone complex to facilitate ERα activation in the absence of
hormone. This makes PRMT6 the third cofactor which is found to be
able to enhance ERα's ligand-independent activity through direct
binding to ERα, after Cyclin D1 and XBP-1 [21,22]. This is also the ﬁrst
report that PRMT6 can regulate cellular function independent of its
enzymatic activity.
PRMT6 can also bind and methylate ERα, PRB and AR, but not GR,
in the presence and absence of ligand. The absence of interaction be-
tween PRMT6 and GR may be due to the difference in cellular localiza-
tion. PRMT6 localizes in the nucleus whereas GR is predominantly
cytoplasmic in the absence of ligand [50]. On the other hand, while
PRMT6 enhanced the ligand-induced effect of PRB, AR, andGRas report-
ed [35], it did not exhibit a signiﬁcant effect on the ligand-independent
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revealed that PRMT6 interacts with the N terminal domain-DBD instead
of the LBD (Data not shown), which may explain why PRMT6 has no
effect on the ligand-independent activity of PRB.
The study indicated that one of the arginine residues targeted
by PRMT6 in ERα is R260, which is also targeted by PRMT1 [36]. The
overlap in target speciﬁcity between PRMT1 and PRMT6 is not surpris-
ing given the fact that both of them recognize arginine/glycine rich
RGG motif and histone H4R3 has been shown to be methylated equally
well by PRMT1 and PRMT6 [51]. It seems that PRMT1 and PRMT6 regu-
late ERα activity through both overlapping and distinct mechanisms.
They both act as secondary coactivators for the ligand-induced genomic
activity of ERα by enhancing the activity of other co-regulators such
as SRC1 [33,35]. In addition, methylation of ERα at R260 by PRMT1
activates ERα non-genomic signaling by promoting ERα binding to
PI3K signaling molecules and activates Akt [36]. Although PRMT6 also
methylates R260, we have not been able to demonstrate that PRMT6
exerts similar effects on the non-genomic ERα signaling. Since PRMT1expression level is higher than PRMT6 in normal tissues [43], it may
be the dominant regulator of this ERα non-genomic signaling pathway.
Moreover, we demonstrate here that PRMT6 also exhibits unique
stimulatory effect on the ligand-independent genomic activity of ERα,
which has not been observed for PRMT1. Overall, PRMT1 and PRMT6
may work together to promote various aspects of ERα signaling—
genomic and non-genomic, ligand-independent and ligand-dependent.
PRMT6 has been reported to repress the expression of several
tumor suppressor genes, including p53, p21(CIP1/WAF1) and p27
by methylating H3R2 at their gene promoter sites [37–40]. PRMT6
also directly methylates and inhibits the activity of tumor suppressor
p16 (INK4A) [52]. The present study together with an earlier study
[35] further highlights that PRMT6 can also function as an oncogene
in breast cancer by promoting both ligand-dependent and ligand-
independent activity of ERα. PRMT6 gene silencing down-regulates
breast cancer cell proliferation both in the presence and absence of
estrogen. The effect of PRMT6 on the ligand-independent activity of
ERα is especially signiﬁcant for anti-estrogen resistant breast cancer.
2077Y. Sun et al. / Biochimica et Biophysica Acta 1843 (2014) 2067–2078It is well established that ligand-independent activation of ERα through
crosstalk with cellular signaling molecules plays a signiﬁcant role
in cancer progression [53,54]. It is conceivable that PRMT6 over-
expression observed in many cases of breast cancer [37,55] can further
bolster ligand-independent ERα activity, enhancing the aggressiveness
of the disease [49]. Thus, small molecule inhibitors that disrupt the
interaction between PRMT6 and ERα may be useful in treating
anti-estrogen resistant breast cancer with PRMT6 over-expression.
In conclusion, the present study provides novel insight into the
regulation of ERα activity by PRMT6. PRMT6 up-regulates both the
ligand-dependent and -independent activity of ERα, but the effect on
the ligand-independent ERα activity is independent of its arginine
methyltransferase activity. This study provides evidence to support
the notion that PRMT6 exerts the effect by competing with Hsp90 for
binding to the C-terminal domain of ERα so as to relieve ERα from the
constraint of chaperone complex. Meanwhile, PRMT6 could function
as a co-activator to facilitate ERα activation. In view of the understand-
ing that many cases of anti-estrogen resistant breast cancers are still
fueled by ligand-independent ERα activity [56], the ﬁndings also raise
an interesting possibility that PRMT6 over-expression may play a part
in driving the progression of anti-estrogen resistant breast cancers via
promoting estrogen-independent ERα activation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.04.008.
Acknowledgment
This project is supported by a grant from the Ministry of Education,
Singapore MOE2011-T2-1-088.
References
[1] J.F. Couse, K.S. Korach, Estrogen receptor null mice: what have we learned and
where will they lead us? Endocr. Rev. 20 (1999) 358–417.
[2] S. Curtis Hewitt, J.F. Couse, K.S. Korach, Estrogen receptor transcription and
transactivation: estrogen receptor knockout mice: what their phenotypes reveal
about mechanisms of estrogen action, Breast Cancer Res. 2 (2000) 345–352.
[3] J.F. Couse, K.S. Korach, Reproductive phenotypes in the estrogen receptor-alpha
knockout mouse, Ann. Endocrinol. 60 (1999) 143–148.
[4] S. Dupont, A. Krust, A. Gansmuller, A. Dierich, P. Chambon, M. Mark, Effect of single
and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta)
on mouse reproductive phenotypes, Development 127 (2000) 4277–4291.
[5] O. Treeck, C. Lattrich, A. Springwald, O. Ortmann, Estrogen receptor beta exerts
growth-inhibitory effects on human mammary epithelial cells, Breast Cancer Res.
Treat. 120 (2009) 557–565.
[6] S. Sommer, S.A. Fuqua, Estrogen receptor and breast cancer, Semin. Cancer Biol. 11
(2001) 339–352.
[7] M.S. Frech, E.D. Halama, M.T. Tilli, B. Singh, E.J. Gunther, L.A. Chodosh, J.A. Flaws, P.A.
Furth, Deregulated estrogen receptor alpha expression in mammary epithelial cells
of transgenic mice results in the development of ductal carcinoma in situ, Cancer
Res. 65 (2005) 681–685.
[8] A. Aranda, A. Pascual, Nuclear hormone receptors and gene expression, Physiol. Rev.
81 (2001) 1269–1304.
[9] R. Metivier, G. Penot, G. Flouriot, F. Pakdel, Synergism between ERalpha
transactivation function 1 (AF-1) and AF-2mediated by steroid receptor coactivator
protein-1: requirement for the AF-1 alpha-helical core and for a direct interaction
between the N- and C-terminal domains, Mol. Endocrinol. 15 (2001) 1953–1970.
[10] S. Kimmins, T.H. MacRae, Maturation of steroid receptors: an example of functional
cooperation among molecular chaperones and their associated proteins, Cell Stress
Chaperones 5 (2000) 76–86.
[11] W.B. Pratt, D.O. Toft, Steroid receptor interactions with heat shock protein and
immunophilin chaperones, Endocr. Rev. 18 (1997) 306–360.
[12] E. Powell, Y. Wang, D.J. Shapiro, W. Xu, Differential requirements of Hsp90 and DNA
for the formation of estrogen receptor homodimers and heterodimers, J. Biol. Chem.
285 (2010) 16125–16134.
[13] L. Bjornstrom, M. Sjoberg, Mechanisms of estrogen receptor signaling: convergence
of genomic and nongenomic actions on target genes, Mol. Endocrinol. 19 (2005)
833–842.
[14] S. Maor, D. Mayer, R.I. Yarden, A.V. Lee, R. Sarfstein, H. Werner, M.Z. Papa, Estrogen
receptor regulates insulin-like growth factor-I receptor gene expression in breast
tumor cells: involvement of transcription factor Sp1, J. Endocrinol. 191 (2006)
605–612.
[15] P.J. Kushner, D.A. Agard, G.L. Greene, T.S. Scanlan, A.K. Shiau, R.M. Uht, P. Webb,
Estrogen receptor pathways to AP-1, J. Steroid Biochem. Mol. Biol. 74 (2000)
311–317.[16] S.R. Johnston, M. Dowsett, Aromatase inhibitors for breast cancer: lessons from the
laboratory, Nat. Rev. Cancer 3 (2003) 821–831.
[17] J.I. MacGregor, V.C. Jordan, Basic guide to the mechanisms of antiestrogen action,
Pharmacol. Rev. 50 (1998) 151–196.
[18] S. Ali, R.C. Coombes, Endocrine-responsive breast cancer and strategies for combating
resistance, Nat. Rev. Cancer 2 (2002) 101–112.
[19] E.A. Musgrove, R.L. Sutherland, Biological determinants of endocrine resistance in
breast cancer, Nat. Rev. Cancer 9 (2009) 631–643.
[20] M. Le Romancer, C. Poulard, P. Cohen, S. Sentis, J.M. Renoir, L. Corbo, Cracking the
estrogen receptor's posttranslational code in breast tumors, Endocr. Rev. 32
(2011) 597–622.
[21] R.M. Zwijsen, E. Wientjens, R. Klompmaker, J. van der Sman, R. Bernards, R.J.
Michalides, CDK-independent activation of estrogen receptor by cyclin D1, Cell 88
(1997) 405–415.
[22] L. Ding, J. Yan, J. Zhu, H. Zhong, Q. Lu, Z. Wang, C. Huang, Q. Ye, Ligand-independent
activation of estrogen receptor alpha by XBP-1, Nucleic Acids Res. 31 (2003)
5266–5274.
[23] G. Bunone, P.A. Briand, R.J. Miksicek, D. Picard, Activation of the unliganded estrogen
receptor by EGF involves the MAP kinase pathway and direct phosphorylation,
EMBO J. 15 (1996) 2174–2183.
[24] P.B. Joel, J. Smith, T.W. Sturgill, T.L. Fisher, J. Blenis, D.A. Lannigan, pp90rsk1 regulates
estrogen receptor-mediated transcription through phosphorylation of Ser-167, Mol.
Cell. Biol. 18 (1998) 1978–1984.
[25] S. Kato, H. Endoh, Y. Masuhiro, T. Kitamoto, S. Uchiyama, H. Sasaki, S. Masushige, Y.
Gotoh, E. Nishida, H. Kawashima, D. Metzger, P. Chambon, Activation of the estrogen
receptor through phosphorylation by mitogen-activated protein kinase, Science 270
(1995) 1491–1494.
[26] A.S. Coutts, L.C.Murphy, Elevatedmitogen-activated protein kinase activity in estrogen-
nonresponsive human breast cancer cells, Cancer Res. 58 (1998) 4071–4074.
[27] V.S. Sivaraman, H. Wang, G.J. Nuovo, C.C. Malbon, Hyperexpression of mitogen-
activated protein kinase in human breast cancer, J. Clin. Invest. 99 (1997)
1478–1483.
[28] J.M. Gee, J.F. Robertson, I.O. Ellis, R.I. Nicholson, Phosphorylation of ERK1/2
mitogen-activated protein kinase is associated with poor response to anti-hormonal
therapy and decreased patient survival in clinical breast cancer, Int. J. Cancer 95
(2001) 247–254.
[29] R.M. Zwijsen, R.S. Buckle, E.M. Hijmans, C.J. Loomans, R. Bernards, Ligand-
independent recruitment of steroid receptor coactivators to estrogen receptor
by cyclin D1, Genes Dev. 12 (1998) 3488–3498.
[30] X.L. Xu, S.Z. Chen, W. Chen, W.H. Zheng, X.H. Xia, H.J. Yang, B. Li, W.M. Mao, The
impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers:
a meta-analysis, Breast Cancer Res. Treat. 139 (2013) 329–339.
[31] Y. Zhu, B. Singh, S. Hewitt, A. Liu, B. Gomez, A. Wang, R. Clarke, Expression patterns
among interferon regulatory factor-1, human X-box binding protein-1, nuclear
factor kappa B, nucleophosmin, estrogen receptor-alpha and progesterone receptor
proteins in breast cancer tissue microarrays, Int. J. Oncol. 28 (2006) 67–76.
[32] B.P. Gomez, R.B. Riggins, A.N. Shajahan, U. Klimach, A. Wang, A.C. Crawford, Y. Zhu,
A. Zwart, M. Wang, R. Clarke, Human X-box binding protein-1 confers both estrogen
independence and antiestrogen resistance in breast cancer cell lines, FASEB J. 21
(2007) 4013–4027.
[33] S.S. Koh, D. Chen, Y.H. Lee,M.R. Stallcup, Synergistic enhancement of nuclear receptor
function by p160 coactivators and two coactivators with protein methyltransferase
activities, J. Biol. Chem. 276 (2001) 1089–1098.
[34] C. Qi, J. Chang, Y. Zhu, A.V. Yeldandi, S.M. Rao, Y.J. Zhu, Identiﬁcation of protein
arginine methyltransferase 2 as a coactivator for estrogen receptor alpha, J. Biol.
Chem. 277 (2002) 28624–28630.
[35] M.J. Harrison, Y.H. Tang, D.H. Dowhan, Protein argininemethyltransferase 6 regulates
multiple aspects of gene expression, Nucleic Acids Res. 38 (2010) 2201–2216.
[36] M. Le Romancer, I. Treilleux, N. Leconte, Y. Robin-Lespinasse, S. Sentis, K.
Bouchekioua-Bouzaghou, S. Goddard, S. Gobert-Gosse, L. Corbo, Regulation of
estrogen rapid signaling through arginine methylation by PRMT1, Mol. Cell 31
(2008) 212–221.
[37] S. Phalke, S. Mzoughi, M. Bezzi, N. Jennifer, W.C. Mok, D.H. Low, A.A. Thike, V.A.
Kuznetsov, P.H. Tan, P.M. Voorhoeve, E. Guccione, p53-Independent regulation of
p21Waf1/Cip1 expression and senescence by PRMT6, Nucleic Acids Res. 40 (2012)
9534–9542.
[38] M. Neault, F.A. Mallette, G. Vogel, J. Michaud-Levesque, S. Richard, Ablation of
PRMT6 reveals a role as a negative transcriptional regulator of the p53 tumor
suppressor, Nucleic Acids Res. 40 (2012) 9513–9521.
[39] M.A. Kleinschmidt, P. deGraaf, H.A. van Teeffelen, H.T. Timmers, Cell cycle regulation
by the PRMT6 arginine methyltransferase through repression of cyclin-dependent
kinase inhibitors, PLoS One 7 (2012) e41446.
[40] C. Stein, S. Riedl, D. Ruthnick, R.R. Notzold, U.M. Bauer, Theargininemethyltransferase
PRMT6 regulates cell proliferation and senescence through transcriptional repression
of tumor suppressor genes, Nucleic Acids Res. 40 (2012) 9522–9533.
[41] D.H. Dowhan, M.J. Harrison, N.A. Eriksson, P. Bailey, M.A. Pearen, P.J. Fuller, J.W.
Funder, E.R. Simpson, P.J. Leedman, W.D. Tilley, M.A. Brown, C.L. Clarke, G.E.
Muscat, Protein arginine methyltransferase 6-dependent gene expression and
splicing: association with breast cancer outcomes, Endocr. Relat. Cancer. 19
(2012) 509–526.
[42] G. Sivaramakrishnan, Y. Sun, S.K. Tan, V.C. Lin, Dynamic localization of tripartite
motif-containing 22 in nuclear and nucleolar bodies, Exp. Cell Res. 315 (2009)
1521–1532.
[43] A. Frankel, N. Yadav, J. Lee, T.L. Branscombe, S. Clarke, M.T. Bedford, The novel
human protein arginine N-methyltransferase PRMT6 is a nuclear enzyme displaying
unique substrate speciﬁcity, J. Biol. Chem. 277 (2002) 3537–3543.
2078 Y. Sun et al. / Biochimica et Biophysica Acta 1843 (2014) 2067–2078[44] Q. Hu, Y.S. Kwon, E. Nunez, M.D. Cardamone, K.R. Hutt, K.A. Ohgi, I. Garcia-Bassets, D.
W. Rose, C.K. Glass, M.G. Rosenfeld, X.D. Fu, Enhancing nuclear receptor-induced
transcription requires nuclear motor and LSD1-dependent gene networking in
interchromatin granules, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 19199–19204.
[45] P.R. Cook, The organization of replication and transcription, Science 284 (1999)
1790–1795.
[46] Y. Zhang, C.H.Wong, R.Y. Birnbaum, G. Li, R. Favaro, C.Y. Ngan, J. Lim, E. Tai, H.M. Poh,
E.Wong, F.H.Mulawadi,W.K. Sung, S. Nicolis, N. Ahituv, Y. Ruan, C.L.Wei, Chromatin
connectivity maps reveal dynamic promoter-enhancer long-range associations,
Nature 504 (2013) 306–310.
[47] D. Picard, The role of heat shock proteins in the regulation of steroid receptor
function, in: Boston Birkhaüser, L.P. Freedman (Eds.), The Molecular Biology of
Steroid and Nuclear Hormone Receptors, 1998, pp. 1–18.
[48] B. Chambraud, M. Berry, G. Redeuilh, P. Chambon, E.E. Baulieu, Several regions
of human estrogen receptor are involved in the formation of receptor-heat shock
protein 90 complexes, J. Biol. Chem. 265 (1990) 20686–20691.
[49] M. Yoshimatsu, G. Toyokawa, S. Hayami, M. Unoki, T. Tsunoda, H.I. Field, J.D. Kelly, D.
E. Neal, Y. Maehara, B.A. Ponder, Y. Nakamura, R. Hamamoto, Dysregulation of
PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various
types of human cancers, Int. J. Cancer 128 (2010) 562–573.[50] R.J. Hache, R. Tse, T. Reich, J.G. Savory, Y.A. Lefebvre, Nucleocytoplasmic trafﬁcking of
steroid-free glucocorticoid receptor, J. Biol. Chem. 274 (1999) 1432–1439.
[51] D. Hyllus, C. Stein, K. Schnabel, E. Schiltz, A. Imhof, Y. Dou, J. Hsieh, U.M. Bauer,
PRMT6-mediatedmethylation of R2 inhistoneH3 antagonizesH3K4 trimethylation,
Genes Dev. 21 (2007) 3369–3380.
[52] X. Wang, Y. Huang, J. Zhao, Y. Zhang, J. Lu, B. Huang, Suppression of PRMT6-
mediated arginine methylation of p16 protein potentiates its ability to arrest
A549 cell proliferation, Int. J. Biochem. Cell Biol. 44 (2012) 2333–2341.
[53] J. Shou, S. Massarweh, C.K. Osborne, A.E. Wakeling, S. Ali, H. Weiss, R. Schiff,
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu
cross-talk in ER/HER2-positive breast cancer, J. Natl. Cancer Inst. 96 (2004) 926–935.
[54] M.C. Gutierrez, S. Detre, S. Johnston, S.K. Mohsin, J. Shou, D.C. Allred, R. Schiff, C.K.
Osborne, M. Dowsett, Molecular changes in tamoxifen-resistant breast cancer:
relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein
kinase, J. Clin. Oncol. 23 (2005) 2469–2476.
[55] D. Chen, H. Ma, H. Hong, S.S. Koh, S.M. Huang, B.T. Schurter, D.W. Aswad, M.R.
Stallcup, Regulation of transcription by a protein methyltransferase, Science 284
(1999) 2174–2177.
[56] C.K. Osborne, R. Schiff, Mechanisms of endocrine resistance in breast cancer, Annu.
Rev. Med. 62 (2011) 233–247.
